Recent research have converged on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and DA signaling. While GCGR agonists are commonly employed for treating type 2 diabetes mellitus, their potential impacts on motivation circuits, specifically